*Plasmodium vivax malaria in the Brazilian Amazon* - Malaria is still a major public health problem in Brazil, with 244,000 cases registered in 2012 ([@B95]), with 99.9% of them distributed through the Amazon Basin, including the states of Pará, Rondônia, Amazonas (AM), Mato Grosso, Amapá, Acre and Roraima (saude.gov.br/sivep_malaria). In these areas, the spatial distribution of malaria is not homogenous and changes over time at individual, community, state and national scales ([@B86], de [@B32], [@B33], [@B12], da [@B30], [@B67]). In the Brazilian Amazon, the instability of transmission is the dominant feature of malaria ([@B17]), with exposed populations consisting mostly of migrants from malaria-free areas. In these individuals, the infection is generally accompanied by clinical symptoms of variable degrees of intensity. Nevertheless, during the past few years, epidemiologic studies carried out among individuals with long-term exposure to malaria in Brazil clearly show the existence of symptomless malaria infections ([@B16], [@B6], da [@B30], [@B52]).

Of the five species of malaria parasites known to infect humans, three species occur in Brazil:*P. vivax, Plasmodium falciparum* and *Plasmodium malariae*. Until 1990, the prevalence of *P. falciparum* and *P. vivax* infections was similar with roughly 50% of each species ([@B55], [@B86], [@B53]), while the prevalence of *P. malariae* was very low. After that time, the incidence of both *P. falciparum* and *P. vivax* has decreased, probably due to the intensification of malaria control measures, which included early diagnosis and treatment ([@B53]). However, certain features of the biology of *P. vivax* give this species greater resilience than *P. falciparum*. Whereas *P. falciparum* parasites invade blood cells at various stages of development, *P. vivax* infects reticulocytes and the latter parasite species seems to be more transmissible at low parasite densities ([@B15]). Furthermore, *P. vivax* parasites are associated with the early appearance of infective sexual stages (gametocytes) in the blood and can remain in the liver as dormant hypnozoites responsible for relapses. These unique characteristics of the biology of *P. vivax* make its management and elimination particularly challenging. In fact, as control measures become more effective, the residual malaria burden is increasingly shifting towards *P. vivax* malaria ([@B59]). Consequently, the number of *P. vivax* cases has increased over the years and this malaria parasite species is now responsible for roughly 80% of all malaria cases in the Brazilian Amazon Region ([@B18], [@B52], [@B94]). Although *P. vivax* malaria is often regarded as benign due to its low mortality, its morbidity is high, reducing the prosperity of affected populations. Of note, in the last few years, complicated *P. vivax* clinical malaria has been reported around the world ([@B87], [@B8]), including the Brazilian Amazon area ([@B5], [@B51]).

Finally, in the Amazon, local *P. vivax* populations are extremely genetically diverse and also show substantial genetic differentiation among populations ([@B37], [@B75], [@B74], [@B68], [@B82]). Beyond the complexity of parasite population, it has been proposed that asymptomatic parasite carriage and massive environmental changes - that affect vector abundance and behaviour - are major contributors to malaria transmission in the epidemiologically diverse areas across the Amazon Basin (da [@B31]). It may explain why malaria has proved so difficult to control in the Amazon Basin, where transmission rates remain far below those recorded in tropical Africa.

*The rationale behind P. vivax Duffy binding protein*(PvDBP)*as a blood-stage vaccine candidate* - The invasion of red blood cells (RBCs) by *Plasmodium* merozoites - an essential event in the life cycle of all malaria parasites - is a highly complex, multistep process that is dependent on a cascade of specific molecular interactions ([@B39]). Despite this complexity, time-lapse microscopy of live parasites demonstrates that parasite entry into RBCs is a rapid process that is completed, on average, within 30 s after primary contact of the merozoite ([@B41]). This multistep invasion process requires coordinated activities of host cell attachment, reorientation placing the apical end of the parasite adjacent to the erythrocyte membrane and active penetration of the host cell. Central to this process is the establishment of a structure called a tight or moving junction, which forms a tight connection between the invading parasite and host cell membranes ([@B4]). For *P. vivax*, the formation of this irreversible junction is mediated by the PvDBP, a protein of approximately 140 kDa localised in merozoite apical organelles called micronemes ([@B93], [@B1], [@B3], [@B36]). During invasion, PvDBP is secreted from the micronemes and binds to its cognate host receptor on the reticulocyte surface, the Duffy antigen/receptor for chemokines (DARC) ([@B93], [@B1]). Although *P. vivax* can infect and cause disease in DARC-negative individuals ([@B72], [@B20], [@B58]), this situation seems to be rare and/or occur only in specific areas; so far, no other alternative ligand for *P. vivax* binding to reticulocytes has been identified, which makes the PvDBP one of the most promising *P. vivax* vaccine targets.

PvDBP belongs to the Duffy binding-like erythrocyte-binding protein (DBL-EBP) family, which encompasses other micronemal proteins, such as the DBP of the simian malaria parasite *Plasmodium knowlesi* and the *P. falciparum* ligands EBA-175, EBA-181/JESEBL and EBA-140/BAEBL ([@B78], [@B3], [@B2], [@B57], [@B40]). The members of the DBL-EBP family share a similar gene structure and this homology was used to define six extracellular regions (I-VI) followed by a type I transmembrane domain and a short cytoplasmic tail ([@B3], [@B2]). Common to all EBPs are the two cysteine-rich domains (regions II and VI) in the ectodomain, with the erythrocyte ligand-binding domain lying within region II (DBPII) ([Fig. 1](#f01){ref-type="fig"}). In *P. falciparum*, the EBPs and the reticulocyte-binding-like protein homologues play an important role in phenotypic variation, allowing different parasite isolates to utilise alternative erythrocyte invasion pathways ([@B69], [@B73], [@B89], [@B34]). Until recently, the gene that encodes PvDBP was described as single copy gene ([@B19]). However, new whole genome sequences from field isolates provides evidence for a duplication of the *dbp* gene in *P. vivax*([@B58]). Interestingly, the frequency of the *dbp* duplication was highest in geographical regions where the highest frequencies of *P. vivax*-infected Duffy-negative people were reported. These data suggest that PvDBP is rapidly evolving, possibly in response to constraints imposed by erythrocyte DARC-negativity in some human populations.

Fig. 1: schematic drawing of the *Plasmodium vivax* Duffy binding protein gene structure. Exons are represented as blocks and drawn to scale. Exon 1 encodes a peptide signal sequence, exon 3 encodes a transmembrane domain and exons 4 and 5 encode a cytoplasmic domain. Exon 2 encodes a large protein domain that contains six regions (Roman numerals) as defined by amino acid (aa) sequence identity to Duffy binding-like erythrocyte-binding protein of other *Plasmodium* species (Adams et al. 1992). The erythrocyte-binding domain lies in the 5' cysteine-rich region (region II) and the critical binding residues have been mapped to a 170-aa stretch between cysteines 4-7 (Ranjan & Chitnis 1999).

The PvDBP ligand domain (DBPII) is a 330 amino acid (aa) region characterised by 12 conserved cysteine residues ([@B25]). The critical binding residues have been mapped to a central 170-aa stretch that includes cysteines 4-7 ([@B71], [@B80], [@B92], [@B43], [@B13], [@B14], [@B76]). This is the minimal domain responsible for binding to DARC-positive human reticulocytes. In 2006, the structure of the *P. knowlesi* DBL domain was determined by X-ray crystallography and characterised as an all-helical, monomeric module containing 12 helices spread over three distinct subdomains (SD1-SD3) that are stabilised by intra-SD disulfide bridges ([@B79]). Essential and invariant residues required for recognition of DARC on human erythrocytes were identified within a region on SD2 ([@B80], [@B79], [@B92], [@B43]). Recently, the crystal structure of DBPII was elucidated and a model was proposed of receptor recognition through PvDBP dimerisation upon receptor binding, leading to the formation of a complex composed of two PvDBP and two DARC molecules ([@B13]). Despite the conserved nature of regions spanning the DARC-binding groove and dimer interface, many residues in DBPII are variable and these polymorphisms map to multiple non-functional regions of the protein ([@B90], [@B7], [@B96], [@B48], [@B92], [@B81], [@B42], [@B10], [@B13], [@B70], [@B24], [@B46], [@B45]). Some of these naturally-occurring polymorphisms flank critical residues and it is suggested that protective antibodies that target the functional regions in DBPII lead to disruption of dimerisation and/or prevention of receptor binding ([@B13]). This pattern of diversity is consistent with strong immune selection pressure on DBPII and suggests that allelic variation is an important mechanism of immune evasion ([@B90], [@B28], [@B56], [@B82]). Although PvDBP is a vital ligand for blood-stage infection, its use for vaccine development poses significant challenges. These include: (i) brief exposure of PvDBP to the host immune system, due to its micronemal location ([@B1]) and the rapid kinetics of parasite invasion ([@B35], [@B41]) and (ii) polymorphisms in PvDBP, which seem to be critical for the evasion of host immune response ([@B91]), as further discussed below.

*Naturally-acquired antibodies against PvDBP* - The goal in developing PvDBP as a vaccine directed against asexual blood-stage of *P. vivax* is to elicit an antibody response that inhibits parasite adhesion to DARC-positive human reticulocytes and thereby abrogate merozoite invasion. Unfortunately, the available data on the functional properties of anti-PvDBP antibodies in human populations are still limited ([@B60], [@B23], [@B49], [@B83], [@B27]), partly due to constraints on performing in vitro functional assays in the absence of a continuous culture method for *P. vivax* blood-stages ([@B65]). Consequently, many field studies of immunity to PvDBP have focused on measuring antibodies to recombinant antigens, but paid less attention to approaches that evaluate functionally important immune mechanisms.

*Anti-PvDBP IgG antibodies measured by conventional serology -*Given the limitations of performing functional assays, ELISAs using different recombinant PvDBP proteins have been useful in evaluating the level of PvDBP IgG antibodies in different endemic populations. Using conventional serology, we demonstrated that PvDBP is naturally immunogenic in the Amazon area and that the proportions of PvDBP IgG-positive subjects increased with exposure to malaria, reaching a peak in those subjects with long-term exposure in the Amazon ([Table](#t01){ref-type="table"}) ([@B21]). Of importance, this study provided an additional insight by demonstrating for the first time that cumulative exposure is a determinant that acts independently of host age in the generation of anti-PvDBP IgG response. In fact, we demonstrated that each additional year of exposure to malaria increased the probability of having anti-PvDBP IgG antibodies by 2% ([@B83]). While these previous studies included subjects who were migrants from malaria-free areas of Brazil - whose ages did not correlate with exposure to malaria - further studies were carried-out with native populations of the Amazon area ([@B47]). In this area, a well-established frontier settlement located in AM, a significant proportion of the community (50%) had acquired anti-PvDBP antibodies, with the subject's age being the only strong predictor of seropositivity to PvDBP. Together, these data reinforce the variety of malaria transmission patterns in communities from the Amazon area.

TABLESummary of previous studies reporting naturally-acquired IgG antibody responses to *Plasmodium vivax* Duffy binding protein (PvDBP)*a*Region \[city/state (n)\]Time of malaria exposure \[months (m) or years (y)\]Frequency of responders - ELISA (%)Recombinant PvDBP^*b*^Subjects with inhibitory antibodies^*c*^ (%)ReferencesLatin America (low transmission)     ** **Brazilian Amazon     **  **Belém/Pará (36)\< 1 m14II-IV0Ceravolo et al. (2005, 2008)**  **Terra Nova do Norte/Mato Grosso (47)10 y38-12/87 (14)**  **Apiacás/Mato Grosso (37)17 y65- **  **Buritis/Rondônia (30)7 y43IINATran et al. (2005)**  **Colina/Rondônia (87)21 y70-NA **  **Ribeirinha/Rondônia (177)28 y70-NA **  **Several areas/Pará (220)-44.5IINABarbedo et al. (2007)**  **Granada/Acre (≈360)14 y9-18.6II-IV14-16/50 (28-32)Souza-Silva et al. (2010)Rio Pardo/Amazonas (432)19 y49.5II-IVNAKano et al. (2012)** **Colombia     **  **Pacific Coast/Valle (92)-40.2II-IVNAMichon et al. (1998)**  **Pacific Coast/Chocó and Valle (214)-≈8-12IINAHerrera et al. (2005)**  **Caribbean Coast/Antioquia (185)\> 5 y9IINAMaestre et al. (2010)**  **Western Pacific     ** **Papua New Guinea (high transmission)     **  **Madang (100)-60II-IVNAFraser et al. (1997)**  **Liksul/Madang (551)-80II-IV and IINAXainli et al. (2003)**  **Mugil and Megiar/Madang (206)-72II58/206 (28)King et al. (2008), Cole-Tobian et al. (2009)[^2]

So far, few studies have investigated anti-PvDBP antibody response in Latin America and data are still restricted to endemic areas of Brazil and Colombia (Table). In general, the pattern of antibody response described in these studies corroborated our data that anti-PvDBP antibodies increase with exposure to *P. vivax.* In addition, PvDBP antibodies seem to be biased toward the cytophilic subclasses IgG1 and IgG3 ([@B88], [@B54]).

From our experience in the Amazon area, it has become evident that PvDBP has relatively low immunogenicity, similar to what has been described in other epidemiological contexts. For example, in the Colombian Pacific coastal region, an area of unstable malaria transmission and mainly composed of Afro-Colombian individuals, as well in the Caribbean Coast, less than 40% of the total number of patients sampled responded to PvDBP ([@B61], [@B44], [@B54]). This antibody response profile is quite different from those described in highly endemic areas for malaria, such as Papua New Guinea (PNG), where antibody responses to PvDBP seem to be much more common (60-80%) (Table) and reach a plateau at ages of 15 years and older ([@B98]). In the latter endemic regions, the proportion of individuals developing T cell responses to PvDBP increased rapidly within the first four years of life such that by five-nine years of age 80% of children responded ([@B97]). The cellular response against PvDBP has not yet been evaluated in Latin America.

*DBPII binding inhibitory antibodies (BIAbs)*- Currently, few reports have examined functional antibodies in malaria-exposed populations and most of them were carried-out in the highly endemic areas of PNG ([@B60], [@B49]), which might not be representative of many *P. vivax* endemic regions. Consequently, our goal was to characterise the DBPII BIAbs response in individuals from an area of markedly unstable malaria transmission, as found in the Brazilian Amazon ([Table](#t01){ref-type="table"}). Our results indicate that long-term exposure to malaria in the Brazilian Amazon elicits DBP-specific antibodies that inhibit the binding of different DBPII variants to erythrocytes ([@B23], [@B83]). However, this inhibitory activity was detected only in one third of malaria-exposed subjects, with a moderate correlation between DBPII BIAbs and ELISA anti-PvDBP antibodies.

Despite significant epidemiological and host/parasite genetic differences between the Amazon Basin and PNG, the relatively low frequency of DBPII BIAbs described among long-term residents of the Amazon area (\~30%) was also found in PNG (Table). In fact, in the latter highly endemic area, less than 10% of immune children had acquired a high level of DBPII BIAbs ([@B49]). It is very intriguing that in the Amazon and PNG, the DBPII BIAbs response was remarkably stable over time ([@B49], [@B83]). These findings imply that although the majority of people naturally-exposed to *P. vivax*do not develop antibodies that inhibit the DBPII-DARC interaction, once they are acquired, these inhibitory antibodies seem to be stable under continuous exposure to malaria transmission.

A plausible explanation for the low immunogenicity of PvDBP is the fact that this protein is localised in the micronemes until the beginning of the process of erythrocyte invasion by merozoites ([@B1]). As a consequence of its brief exposure, the host immune system seems to have little opportunity to produces an efficient antibody response. However, the "just-in-time" hypothesis of PvDBP exposure ([@B79]) does not completely explain the large proportion of individuals who remain unresponsive to PvDBP after prolonged exposure to malaria. The reasons for this are not clear, but may relate to the complexity of the immune response, in terms of genetic diversity of both the parasite and human populations. With regard to the genetic diversity of the parasite, several studies now indicate the existence of strain-specificity in the natural immune response against PvDBP ([@B22], [@B29], [@B27]). In a study conducted during a malaria outbreak outside of the Brazilian endemic area, we demonstrated that the majority of responders had developed inhibitory antibodies against the homologous DBPII sequence identified in the outbreak isolate ([@B22]). These findings provided the first clear evidence that naturally-acquired inhibitory antibodies to DBPII are biased towards a specific allele in individuals with no previous exposure to malaria infection ([@B22]). In Thailand, an area of low unstable transmission of *P. vivax*, the inhibitory antibody responses against DBPII also correlated with homologous protection ([@B27]). Similarly, a profile of strain-specific inhibitory activity was frequently observed among asymptomatic children from PNG ([@B29]).

Even though the current data clearly demonstrated strain-specific immunity, we and others have also described strain-transcendent inhibitory responses to DBPII ([@B49], [@B83]). In the Brazilian Amazon area, only individuals with long-term exposure to malaria (roughly 20 years) acquired DBPII BIAbs against different DBPII variants ([@B23]). Similarly, only 9% of asymptomatic children residing in a *P. vivax* hyperendemic area had acquired a significant anti-PvDBP inhibitory antibody response that transcended strain-specificity ([@B49]). These findings highlight the complexity of the immune responses to DBPII, which includes both a strain-specific and strain-transcending component ([@B29]).

Besides PvDBP allelic variation, recent evidence suggests that host genetic polymorphisms might also affect humoral immunity against PvDBP ([@B54], [@B50]). The most relevant finding was that DARC allelic polymorphisms are thought to affect the ability of anti-PvDBP antibodies to block parasite invasion ([@B50]). DARC is encoded by two codominant allele groups *FY\*A* and *FY\*B*, which differ by a single point mutation. Of particular interest is that we recently demonstrated that DBPII inhibitory antibody responses were approximately 50% lower in *FY\*A/FY\*A* and *FY\*B/FY\*B* homozygous individuals when compared with individuals heterozygous for *FY\*A*or*FY\*B*alleles, suggesting a gene-dosage effect ([@B84]). Due to the relevance of these findings for vaccines now in development, it would be pertinent to investigate whether such an association exists in other *P. vivax* malaria endemic countries. In this context, it would be relevant to determine if PvDBP non-responsiveness could be major histocompatibility complex-linked. So far, only a single study investigated the association between human leukocyte antigen (HLA) class II and PvDBP antibodies ([@B85]). Although that study was unable to demonstrate an association between HLA type and PvDBP antibodies, the low number of individuals studied (PvDBP IgG sera, n = 48) precludes any solid conclusions about the highly polymorphic HLA class II and PvDBP antibodies. In this context, follow-up studies are currently in progress in the Amazon area (LH Carvalho, unpublished observations).

*Genetic diversity of PvDBP in the Amazon area* - Analysis of the genetic variability of *P. vivax* isolates from the field revealed that the PvDBP binding domain (region II, DBPII) is highly polymorphic, similar to most blood-stage malaria vaccine candidates, which may facilitate parasite escape from host immune detection. Based on field-studies, it seems clear that this extensive diversity might hamper vaccine development, since variable residues could alter immune recognition of the protein ([@B22], [@B29]). Thus, for development of PvDBP-based vaccine it is important to assess the levels of DBPII genetic diversity among *P. vivax* field isolates. The first data on the variability of PvDBP were obtained for isolates of the parasite from PNG and Colombia ([@B90], [@B7]). Further analyses showed that most of the variable residues lie within a 170-aa region of DBPII and, at that time, there was no evidence that variable residues could interfere with erythrocyte receptor recognition ([@B96]). Later, the same authors confirmed the influence of DBPII polymorphism as a mechanism of immune evasion ([@B91]). Aiming to contribute to efforts towards vaccine development, we initially investigated in the Brazilian Amazon those eight single nucleotide polymorphisms previously suggested to be involved in the immune recognition of PvDBP ([@B91]). Brazilian *P. vivax* isolates showed variability in almost all residues and a strong association of residues at positions 417, 424 and 437, suggesting a synergistic functional effect of these aas, possibly constituting a discontinuous epitope in DBPII ([@B81]) ([Fig. 2](#f02){ref-type="fig"}). The synergistic effect of the duo 417 and 424, including residue 419 were reinforced by the findings that they are part of a block of high linkage disequilibrium and show a clear signature of positive natural selection among Brazilian isolates ([@B82]). In accordance, these three residues were found to be part of an *in silico* DBPII predicted epitope that is recognised by DBPII BIAbs present in sera from PNG ([@B26], [@B82]).

Fig. 2: Duffy binding protein (DBPII) dimeric structure. Subdomain (SD1) (sky blue), SD2 (dark blue) and SD3 (light blue). Critical binding residues are coloured yellow (Asn291, Tyr295, Asn296, Lys297, Phe299 and Val365, Lys366, Lys367, Arg368, Leu369, Phe373, Ile374, Ile376) (VanBuskirk et al. 2004b, , Hans et al. 2005, , Bolton & Garry 2011, , Sampath et al. 2013). Residues that form the putative sulfotyrosine-binding pocket at the dimer interface are coloured purple (Lys273, Arg274 and Gln356). Residues that make contact creating the dimeric architecture are coloured orange (Phe267, Leu270, Ile277, Tyr278, Val282, Tyr363 and Arg274, Glu249) (Batchelor et al. 2011). Polymorphic residues in Brazilian isolates are coloured red (N305N, R308S, L333F, K371E, N375D, R378R, G384D, E385K, K386N, H390R, S398T, T404R, N417K, I419M, L424I, W437R, I464I, Q486E, I503K) (Sousa et al. 2006, 2010, 2010). Images modelled in PyMol on the DBPII dimer structure (Batchelor et al. 2011).

Subsequently, we compared the DBPII diversity among *P. vivax* isolates from different countries worldwide, including samples from the Brazilian Amazon. In general, high levels of haplotype diversity were observed among isolates independent of the malaria endemicity ([@B63]). These data on the nucleotide diversity of DBPII also provided evidence that recombination plays an important role in determining the haplotype structure of DBPII ([@B56], [@B82]). In addition, it was possible to demonstrate that natural selection acts differentially across the DBPII sequence, with neutrally evolving codons as well as codons evolving under diversifying selection ([@B28], [@B56], [@B82]). Of importance, positive natural selection preferentially acts on epitopes in DBPII, which also have greater nucleotide diversity ([@B28], [@B82], [@B46], [@B45]). This is in agreement with the hypothesis that immune selection is the major evolutionary force that drives the generation of new PvDBP variants. In accordance with these findings, field-studies carried-out in different malaria endemic areas showed that naturally-acquired inhibitory antibodies to DBPII are biased towards a specific allele ([@B22], [@B29]). This is relevant because current vaccine development is based only on the DBPII haplotype of the *P. vivax* laboratory-adapted strain Sal-1 ([@B99], [@B9], [@B62]). However, this haplotype has been found at only a low frequency in most Amazon regions and, of note, it seems to be largely restricted to some geographical areas of the world ([@B63]).

Recently, crystallographic and functional studies allowed the identification of the structural regions of PvDBP targeted by inhibitory antibodies ([@B26], [@B13], [@B76]). The findings suggest that some epitopes recognised by BIAbs lie close to the predicted DARC interaction site, suggesting that cause disruption of PvDBP dimerisation and/or prevention of PvDBP receptor binding ([@B13], [@B76]). Despite cumulative knowledge about DBPII structure, there is limited understanding about the molecular basis for protection and immune evasion. Research to date has underlined the importance of the SD2 of DBPII for DARC binding and immune selection ([@B79], [@B13], [@B76]). Nevertheless, [@B77] showed that the SD3 is also important for binding to DARC. Furthermore, inhibitory murine monoclonal antibodies mapped to SD3 recognise epitopes that are strain transcendent ([@B77]). Since this SD is relatively conserved it could form the basis of a strain-transcending vaccine against *P. vivax*.

Aiming towards universal, strain-transcending anti-PvDBP immunity, the current strategies of vaccine development have been focusing on immune responses against more conserved DBPII epitopes. An interesting approach was based on the hypothesis that the polymorphic residues, which are not functionally important for erythrocyte-binding, but flank the receptor binding motif of DBPII, comprise variant epitopes that tend to divert the immune response away from more conserved epitopes ([@B64]). In this respect, these authors demonstrated that immunisation with a synthetic antigen lacking the immunodominant DBPII variant epitopes enabled the development of immune responses towards the more conserved neutralising epitopes, which are the potential targets of a strain-transcending immunity. Another promising vaccine approach should be immunisation with a multiple component vaccine representing the major DBPII haplotypes ([@B66]). In this context, a preliminary analysis of the worldwide DBPII sequences allowed us to determine that seven haplotypes should be the minimum number of haplotypes to be included in a DBP-based vaccine of broad coverage ([@B63]).

*Concluding remarks* - PvDBP is likely to be exposed on the merozoite surface during invasion, enabling it to bind to its receptor and, thus, making it accessible to serum antibodies. While measuring antibodies to recombinant PvDBP by ELISA is a simple and robust procedure widely used in human population studies, it provides little functional information when used alone. As a consequence, field-studies on PvDBP immune response should include assays to evaluate the functional proprieties of anti-PvDBP antibodies. Cross-sectional and cohort studies carried-out in the Amazon area provide evidence that the majority of people naturally-exposed to *P. vivax*do not develop antibodies that inhibit the DBPII-DARC interaction. Nevertheless, once they are acquired, these inhibitory antibodies seem to be stable under continuous exposure to malaria transmission. These results are intriguing and seem to be a common phenomenon in other endemic areas, including those highly endemic areas of PNG, where most individuals have developed clinical immunity to malaria ([@B49]). The results presented here also provide strong evidence that DARC interaction site and epitopes on PvDBP have sufficient overlap for antibodies to disrupt dimerisation and/or inhibit binding ([@B13], [@B76]) and provide support for the role of allelic diversity in anti-PvDBP immune responses. Of note, while our findings point to allelic variation eliciting a strain-specific immunity, individuals with long-term exposure in the Amazon area acquired DBPII antibodies that inhibit in vitro binding of different DBPII variants to erythrocytes. Future challenges include understanding why only few malaria exposed-individuals develop an immune response able to inhibit DBPII-DARC interaction and to establish whether PvDBP inhibitory immune response predicts partial protection from infection and/or disease, as suggested by others ([@B49]). We hope that these findings from unstable malaria transmission areas contribute to current efforts towards vaccine development and may facilitate future clinical trials in areas of unstable malaria transmission.
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